The pituitary tumour‐transforming gene 1/delta‐like homologue 1 pathway plays a key role in liver fibrogenesis. (30th January 2022)
- Record Type:
- Journal Article
- Title:
- The pituitary tumour‐transforming gene 1/delta‐like homologue 1 pathway plays a key role in liver fibrogenesis. (30th January 2022)
- Main Title:
- The pituitary tumour‐transforming gene 1/delta‐like homologue 1 pathway plays a key role in liver fibrogenesis
- Authors:
- Perramón, Meritxell
Carvajal, Silvia
Reichenbach, Vedrana
Fernández‐Varo, Guillermo
Boix, Loreto
Macias‐Muñoz, Laura
Melgar‐Lesmes, Pedro
Bruix, Jordi
Melmed, Shlomo
Lamas, Santiago
Jiménez, Wladimiro - Abstract:
- Abstract: Background and Aims: PTTG1 is almost undetectable in adult livers but is highly expressed in hepatocarcinoma. While little is known about its involvement in liver fibrosis, PTTG1 expression is associated with DLK1 . We assessed the role of the PTTG1/DLK1 pathway in fibrosis progression and the potential therapeutic effect of PTTG1 silencing in fibrosis. Methods: Pttg1 and Dlk1 were studied in liver and isolated cell populations of control and fibrotic rats and in human liver biopsies. The fibrotic molecular signature was analysed in Pttg1 −/− and Pttg1 +/+ fibrotic mice. Finally, Pttg1 silencing was evaluated in rats as a novel antifibrotic therapy. Results: Pttg1 and Dlk1 mRNA selectively increased in fibrotic rats paralleling fibrosis progression. Serum DLK1 concentrations correlated with hepatic collagen content and systemic and portal haemodynamics. Human cirrhotic livers showed greater PTTG1 and DLK1 transcript abundance than non‐cirrhotic, and reduced collagen was observed in Pttg1 Pttg1 −/− mice. The liver fibrotic molecular signature revealed lower expression of genes related to extracellular matrix remodelling including Mmp 8 and 9 and Timp4 and greater eotaxin and Mmp13 than fibrotic Pttg1 +/+ mice. Finally, interfering Pttg1 resulted in reduced liver fibrotic area, lower α‐Sma and decreased portal pressure than fibrotic animals. Furthermore, Pttg1 silencing decreased the transcription of Dlk1, collagens I and III, Pdgfrβ, Tgfrβ, Timp1, Timp2 and Mmp2 .Abstract: Background and Aims: PTTG1 is almost undetectable in adult livers but is highly expressed in hepatocarcinoma. While little is known about its involvement in liver fibrosis, PTTG1 expression is associated with DLK1 . We assessed the role of the PTTG1/DLK1 pathway in fibrosis progression and the potential therapeutic effect of PTTG1 silencing in fibrosis. Methods: Pttg1 and Dlk1 were studied in liver and isolated cell populations of control and fibrotic rats and in human liver biopsies. The fibrotic molecular signature was analysed in Pttg1 −/− and Pttg1 +/+ fibrotic mice. Finally, Pttg1 silencing was evaluated in rats as a novel antifibrotic therapy. Results: Pttg1 and Dlk1 mRNA selectively increased in fibrotic rats paralleling fibrosis progression. Serum DLK1 concentrations correlated with hepatic collagen content and systemic and portal haemodynamics. Human cirrhotic livers showed greater PTTG1 and DLK1 transcript abundance than non‐cirrhotic, and reduced collagen was observed in Pttg1 Pttg1 −/− mice. The liver fibrotic molecular signature revealed lower expression of genes related to extracellular matrix remodelling including Mmp 8 and 9 and Timp4 and greater eotaxin and Mmp13 than fibrotic Pttg1 +/+ mice. Finally, interfering Pttg1 resulted in reduced liver fibrotic area, lower α‐Sma and decreased portal pressure than fibrotic animals. Furthermore, Pttg1 silencing decreased the transcription of Dlk1, collagens I and III, Pdgfrβ, Tgfrβ, Timp1, Timp2 and Mmp2 . Conclusions: Pttg1 / Dlk1 are selectively overexpressed in the cirrhotic liver and participate in ECM turnover regulation. Pttg1 disruption decreases Dlk1 transcription and attenuates collagen deposition. PTTG1/DLK1 signalling is a novel pathway for targeting the progression of liver fibrosis. … (more)
- Is Part Of:
- Liver international. Volume 42:Number 3(2022)
- Journal:
- Liver international
- Issue:
- Volume 42:Number 3(2022)
- Issue Display:
- Volume 42, Issue 3 (2022)
- Year:
- 2022
- Volume:
- 42
- Issue:
- 3
- Issue Sort Value:
- 2022-0042-0003-0000
- Page Start:
- 651
- Page End:
- 662
- Publication Date:
- 2022-01-30
- Subjects:
- extracellular matrix -- fibrosis -- gene therapy -- liver -- siRNA
Liver -- Periodicals
Liver -- Diseases -- Periodicals
616.362 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1478-3231 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/liv.15165 ↗
- Languages:
- English
- ISSNs:
- 1478-3223
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5280.514000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 21193.xml